Online inquiry

IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9011MR)

This product GTTS-WQ9011MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MST1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001244937.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4486
UniProt ID Q04912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9011MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15814MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ6203MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ6483MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4658MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ8988MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ2893MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ12461MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12045MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW